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related length of hospi-
tal stay was shortened by 
about 2 days (P=.039). Th e 
study found no diff erence 
in pneumonia-related hos-
pitalizations among all 
vaccinated patients.
Effect on younger 
patients is unclear
Because the investigators 
didn’t analyze asthma-
related or pneumonia-
related hospitalizations 
among asthmatic patients 64 years and young-
er, the eff ect of pneumococcal vaccination on 
this younger subgroup can’t be diff erentiated 
from the entire group of patients with asthma.1 
What about pneumococcal hospitalization?
A retrospective, case-controlled cohort study 
examined the impact of pneumococcal vac-
cination on any pneumococcal-related hospi-
talization in patients with COPD or asthma.2 
Th e study included 2746 adults with asthma 
(74.2% younger than 64 years) who were fol-
lowed for about 2.1 years before and 2.6 years 
after vaccination. 
Investigators found no signifi cant diff er-
ences in risk of pneumococcal-related hos-
pitalization between asthma patients and 
controls throughout the study. Th ey didn’t 
evaluate asthma-related hospital admissions. 
Impact of vaccine on invasive disease 
in younger asthma patients?
A retrospective, nested, case-controlled study 
examined the relationship between asthma 
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EVIDENCE-BASED ANSWER
A adults between the ages of  and  years who  have chronic lung disease, including asthma, should 
get the vaccine, as should all patients 65 years and older 
(strength of recommendation [SOR]: C, consensus guide-
lines). Evidence doesn’t support routine vaccination of 
children with asthma or adults younger than 65 years who 
don’t have chronic lung disease to decrease asthma-related 
or pneumonia-related hospitalizations (SOR: B, 1 retrospec-
tive cohort study and 1 retrospective, case-controlled cohort 
study). 
Evidence summary
A 5-year retrospective cohort study of 9170 
patients evaluated the eff ect of pneumococ-
cal vaccination on incidence and length of 
all-cause hospitalizations and hospitalizations 
related to respiratory and otorhinolaryngologic 
syndromes, including asthma and pneumonia.1 
Th e vaccine was given to all patients older than 
64 years (7834 patients [85%]) and any patient 
at risk for pneumococcal infection or compli-
cations, including patients with asthma, chron-
ic obstructive pulmonary disease (COPD), 
bronchitis, chronic respiratory disease, cardio-
vascular disease, chronic renal failure, diabetes 
mellitus, immunodefi ciency, and functional or 
anatomic asplenia (1336 patients [15%]).
Th e number of all-cause hospitaliza-
tions was reduced by 58% in patients who 
received the pneumococcal vaccine (relative 
risk [RR]=0.96; 95% confi dence interval [CI], 
0.94-0.98). In vaccinated patients with asthma 
(793 patients [8.7%]), asthma-related hospi-
talizations decreased by 78% (RR=1.82; 95% 
CI, 1.35-2.45; NNT=49) and average asthma-
John Brock Harris, 
PharmD, BCPS, and 
Lisa Edgerton, PharmD, 
BCPS, CPP
New Hanover 
Regional Medical Center, 
Wilmington, NC
Karen Stafford, MLS
Southeast Area Health 
Education Center Medical 
Library, Wilmington, NC
Pneumococcal 
vaccine is 
indicated for 
adults between 
19 and 64 years 
of age who have 
asthma or other 
chronic lung 
disease.
and invasive pneumococcal disease (IPD) in 
6985 patients enrolled in Tennessee’s Med-
icaid program.3 Patients 2 to 49 years of age 
with any IPD diagnosis were identifi ed us-
ing International Classifi cation of Diseases 
(ICD-9-CM) codes and followed for 8 years. 
Asthma patients without coexisting con-
ditions that confer a high risk of IPD (such as 
diabetes, cardiac disease, and infection with 
human immunodefi ciency virus) had a 14.7% 
risk of IPD compared with a risk of only 7.4% in 
age-matched controls (adjusted odds ratio=2.4; 
95% CI, 1.7-3.4). Th e authors concluded that 
this Medicaid population with asthma had an 
increased incidence of IPD of 1 to 3 cases annu-
ally per 10,000 people. Th e eff ect of pneumococ-
cal vaccination on the incidence of IPD in these 
younger asthma patients is unknown, however.3
Recommendations
Th e National Asthma Education and Pre-
vention Program (NAEPP)4 and the Global 
Initiative for Asthma (GINA)5 make no recom-
mendations regarding the administration of 
the pneumococcal vaccine. 
Th e Advisory Committee on Immuniza-
tion Practices (ACIP) recommends vaccina-
tion for all adults 65 years and older and adults 
19 years and older with chronic lung disease, 
including asthma, or other chronic medical 
conditions such as cardiovascular diseases, 
diabetes, chronic liver diseases, chronic al-
coholism, chronic renal failure, asplenia, and 
other immunocompromising conditions.6 
Th e British Department of Health recom-
mends vaccination with either the 7-valent 
conjugate or the 23-valent polysaccharide 
pneumococcal vaccine for all asthma pa-
tients taking systemic steroids longer than 1 
month at a dose equivalent to prednisolone 
20 mg daily and for children weighing less 
than 20 kg who take daily steroids at a dose of 
≥1 mg/kg. Effi  cacy studies aren’t available to 
support this recommendation.7 
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